Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
…, CS Cardellino, K Koliakou, EI Katsigianni… - Nature medicine, 2021 - nature.com
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
A systematic review of the economic evaluations of Enzyme Replacement Therapy in Lysosomal Storage Diseases
EI Katsigianni, P Petrou - Cost Effectiveness and Resource Allocation, 2022 - Springer
Objective The objective of this paper is to assess the economic profile of Enzyme Replacement
Therapy (ERT) to symptomatic patients with Pompe, Fabry, Gaucher disease and …
Therapy (ERT) to symptomatic patients with Pompe, Fabry, Gaucher disease and …
Author correction: early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled …
…, CS Cardellino, K Koliakou, EI Katsigianni… - Nature Medicine, 2021 - nature.com
… Eleni-Ioanna Katsigianni … Katerina Koliakou, Eleni-Ioanna Katsigianni, Styliani Micha,
Orestis Liatsis-Douvitsas, Maria Mouktaroudi, Eleni Florou, Miltiades Kyprianou & …
Orestis Liatsis-Douvitsas, Maria Mouktaroudi, Eleni Florou, Miltiades Kyprianou & …
Early anakinra treatment for COVID-19 guided by urokinase plasminogen receptor
…, A Argyraki, CS Cardellino, EI Katsigianni… - medRxiv, 2021 - medrxiv.org
Background In a previous open-label trial, early anakinra treatment guided by elevated
soluble urokinase plasminogen activator receptor (suPAR) prevented progression of COVID-19 …
soluble urokinase plasminogen activator receptor (suPAR) prevented progression of COVID-19 …
Early Treatment of COVID-19 Pneumonia with Anakinra Guided by Urokinase Plasminogen Receptor
…, A Argyraki, CS Cardellino, K Koliakou, EI Katsigianni… - 2021 - researchsquare.com
Early recognition of risk and start of treatment may improve unfavorable outcome of COVID-19.
In the SAVE-MORE double-blind randomized trial, 594 patients with pneumonia without …
In the SAVE-MORE double-blind randomized trial, 594 patients with pneumonia without …
Economic burden of Gaucher disease at a tertiary care public hospital in Mumbai
SP Mhatre, M Muranjan, NJ Gogtay - Indian Journal of Pediatrics, 2023 - Springer
Objectives To estimate the economic burden of patients diagnosed with Gaucher disease at
a public hospital from a societal perspective. Methods Data from 30 Gaucher patients …
a public hospital from a societal perspective. Methods Data from 30 Gaucher patients …
Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease
L van Dussen, M Biegstraaten, CEM Hollak… - Orphanet journal of rare …, 2014 - Springer
Objective To evaluate the cost-effectiveness of enzyme replacement therapy (ERT) compared
to standard medical care without ERT in the Dutch cohort of patients with type 1 Gaucher …
to standard medical care without ERT in the Dutch cohort of patients with type 1 Gaucher …
[CITATION][C] Early Anakinra Treatment for COVID-19 Guided by Urokinase Plasminogen Receptor (preprint)
…, A Argyraki, CS Cardellino, EI Katsigianni… - 2021
[CITATION][C] Early Treatment of COVID-19 Pneumonia with Anakinra Guided by Urokinase Plasminogen Receptor (preprint)
…, A Argyraki, CS Cardellino, K Koliakou, EI Katsigianni… - 2021
[CITATION][C] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled …
…, K Koliakou, EI Katsigianni… - NATURE …, 2021 - … HEIDELBERGER PLATZ 3, BERLIN …
